Related Experiment Videos
The Gambia Hepatitis Intervention Study. The Gambia Hepatitis Study Group
Insights
The Gambia Hepatitis Intervention Study evaluated the hepatitis B (HBV) vaccine
Area of Science:
- Hepatology
- Vaccinology
- Public Health
Background:
- Hepatocellular cancer (HCC) and chronic liver diseases pose significant global health challenges.
- Hepatitis B virus (HBV) infection is a primary cause of HCC and chronic liver disease worldwide.
- Early infant vaccination is a key strategy for preventing HBV transmission and sequelae.
Purpose of the Study:
- To evaluate the long-term efficacy of the hepatitis B (HBV) vaccine in preventing hepatocellular cancer (HCC) and chronic liver diseases.
- To assess the impact of a national infant HBV vaccination program on liver disease incidence.
- To establish a robust surveillance system for monitoring liver disease trends in a large cohort.
Main Methods:
- A large-scale, prospective vaccination study involving approximately 600,000 infants in The Gambia.
- Randomized introduction of national hepatitis B (HBV) vaccination over a 4-year period.
- Long-term (30-40 years) national surveillance for hepatocellular cancer and chronic liver diseases.
- Case tracing to link liver disease occurrences with vaccination status.
Main Results:
- The study design facilitates the evaluation of HBV vaccine efficacy in a real-world, national public health program.
- Data collection includes identification, vaccination records, and long-term health outcomes.
- The surveillance system is designed to detect incidence of HCC and chronic liver diseases over several decades.
Conclusions:
- The Gambia Hepatitis Intervention Study is a landmark project to determine the effectiveness of infant HBV vaccination in preventing liver cancer and chronic liver disease.
- The study's design allows for robust, long-term evaluation of public health interventions.
- Findings will inform global strategies for hepatitis B prevention and control.
Abstract:
The Gambia Hepatitis Intervention Study is a large-scale vaccination project in The Gambia, initiated in July 1986, in which the introduction of national hepatitis B (HBV) vaccination of young infants progressively over a 4-year period is proposed. During this time it is anticipated that about 600,000 infants will receive a course of HBV vaccine and a similar number will not receive the vaccine. All children in the study will receive the normal childhood vaccinations. Identification data for each child will be collected and stored with information on their vaccination records. A national surveillance system will be set up to detect new cases of hepatocellular cancer and other chronic liver diseases over a period of 30 to 40 years. An attempt will be made to trace each case, of relevant age, to determine if they are included in the HBV vaccination study. In this way, the efficacy of HBV vaccine in the prevention of HCC and chronic liver diseases will be evaluated. Details of the study design are discussed.